As more states move to decriminalize cannabis, the regulatory framework becomes more complicated. How can companies successfully navigate federal and state laws?
The FDA issued warning letters to several CBD companies for selling unapproved products with unsubstantiated medical claims.
Not all products have to meet the U.S. Federal Drug Administration’s (FDA) approval: certain biologics and dietary supplements do not require it, and there are alternative pathways for OTC drugs and other products to skip the process.
The recent FDA hearing raised the the marketing of recreational CBD as a medical product--an act which falls in violation of federal and state laws. This hearing was well attended by companies and individuals with invested interest in pushing their...